Your browser doesn't support javascript.
loading
Computationally-Guided Development of a Chelated NHC-P Iridium(I) Complex for the Directed Hydrogen Isotope Exchange of Aryl Sulfones.
Kerr, William J; Knox, Gary J; Reid, Marc; Tuttle, Tell; Bergare, Jonas; Bragg, Ryan A.
  • Kerr WJ; Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow G1 1XL, Scotland, U.K.
  • Knox GJ; Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow G1 1XL, Scotland, U.K.
  • Reid M; Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow G1 1XL, Scotland, U.K.
  • Tuttle T; Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow G1 1XL, Scotland, U.K.
  • Bergare J; Early Chemical Development, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg SE-43183, Sweden.
  • Bragg RA; Early Chemical Development, Pharmaceutical Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
ACS Catal ; 10(19): 11120-11126, 2020 Oct 02.
Article en En | MEDLINE | ID: mdl-33123410
ABSTRACT
Herein, we report the rational, computationally-guided design of an iridium(I) catalyst system capable of enabling directed hydrogen isotope exchange (HIE) with the challenging sulfone directing group. Substrate binding energy was used as a parameter to guide rational ligand design via an in silico catalyst screen, resulting in a lead series of chelated iridium(I) NHC-phosphine complexes. Subsequent preparative studies show that the optimal catalyst system displays high levels of activity in HIE, and we demonstrate the labeling of a broad scope of substituted aryl sulfones. We also show that the activity of the catalyst is maintained at low pressures of deuterium gas and apply these conditions to tritium radiolabeling, including the expedient synthesis of a tritium-labeled drug molecule.